Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
2 High-Yield Dividend Stocks That Are Bargain Buys Right Now
09:00am, Thursday, 20'th Mar 2025
Healthcare is a defensive sector that is more resilient to economic downturns than most others. That's one of several reasons it is home to solid dividend stocks, including Pfizer (PFE -0.49%) and Bri
BofA Securities Says No Rate Cuts in 2025 or 2026: Grab These High-Yield Dividend Blue Chips Now
08:16am, Thursday, 20'th Mar 2025
Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciation has contributed 68%.
Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note
06:45pm, Wednesday, 19'th Mar 2025
Bristol Myers Squibb (BMY) reachead $60.08 at the closing of the latest trading day, reflecting a +0.3% change compared to its last close.
10 Undervalued Dividend Growth Stocks: March 2025
09:00am, Wednesday, 19'th Mar 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, an
Bristol-Myers Squibb: Why I'm Still Bullish
05:09pm, Tuesday, 18'th Mar 2025
I reiterate my "Buy" rating on Bristol-Myers Squibb due to its undervaluation, strong growth portfolio, and significant cost-saving initiatives. BMY's drug portfolio expansion and strategic productivi
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
06:51pm, Thursday, 13'th Mar 2025
Bristol Myers Squibb (BMY) closed at $60.28 in the latest trading session, marking a +0.79% move from the prior day.
With Nasdaq 100 in Correction, 4 High-Yield Dividend Giants Are Near 52-Week Highs
06:47am, Thursday, 13'th Mar 2025
Investors love dividend stocks, especially the high-yield variety because they offer a significant income stream and have massive total return potential.
Bristol-Myers Squibb Company (BMY) Presents at Leerink Partners 2025 Global Healthcare Conference (Transcript)
05:46pm, Wednesday, 12'th Mar 2025
Bristol-Myers Squibb Company (NYSE:BMY ) Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ET Company Participants Roland Chen - Head of Development for Immunology, Cardi
TSVT Up on Acquisition Agreement With BMY for $286 Million
04:00pm, Tuesday, 11'th Mar 2025
2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.
03:31pm, Tuesday, 11'th Mar 2025
NEW YORK , March 11, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by 2seventy bio, Inc. (NASDAQ: TSVT) and its board of directors concerning the proposed a
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
10:17am, Tuesday, 11'th Mar 2025
On Monday, Bristol Myers Squibb & Co BMY agreed to acquire 2seventy bio, Inc. TSVT at $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 milli
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
07:17am, Tuesday, 11'th Mar 2025
Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday.
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
10:17pm, Monday, 10'th Mar 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the out
